Skip to main content
Eric Small, MD, Oncology, San Francisco, CA, UCSF Medical Center

EricJ.SmallMD

Oncology San Francisco, CA

Genitourinary Oncology, Hematologic Oncology

Director, Investigational Trials Resource, UCSF Helen Diller Family Comprehensive Cancer Center; Chief, Division of Hematology/Oncology, UCSF; Deputy Director and Director of Clinical Sciences, UCSF Helen Diller Family Comprehensive Cancer Center

Dr. Small is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Small's full profile

Already have an account?

Education & Training

  • University of California (San Francisco)
    University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 1988 - 1989
  • Beth Israel Deaconess Medical Center
    Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1985 - 1988
  • Case Western Reserve University School of Medicine
    Case Western Reserve University School of MedicineClass of 1985

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1987 - 2024
  • American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly, 2004-2014
  • America's Top Doctors for Cancer Castle Connolly, 2005-2013
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • First-in-Human Phase I Study of CTT1057, a Novel 18F Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate Specific Membrane Antigen in Prostate Cancer  
    Spencer C Behr, Hao G Nguyen, Thomas A Hope, Kirsten L Greene, Matthew R Cooperberg, Robert R Flavell, Eric J Small, Peter R Carroll, Journal of Nuclear Medicine
  • Corrigendum to ‘Cabozantinib Versus Sunitinib as Initial Therapy for Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk (Alliance A031203 CABOSUN Randomised ...  
    Toni K Choueiri, Olwen Hahn, Thomas Olencki, Eric J Small, Shaker Dakhil, Darren R Feldman, European Journal of Cancer
  • Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall Survival  
    Eric J Small, David I Quinn, Clinical Cancer Research

Lectures

  • Efficacy of apalutamide (APA) plus ongoing androgen deprivation therapy (ADT) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) and ba... 
    2019 ASCO Annual Meeting - 6/1/2019

Authored Content

  • Corrigendum to ‘Cabozantinib Versus Sunitinib as Initial Therapy for Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk (Alliance A031203 CABOSUN Randomised Trial): Progression-Free Survival by Independent Review and Overall Survival Update’ [Eur J Cancer 94 (May 2018) 115–125]September 2018
  • Cabozantinib Versus Sunitinib as Initial Therapy for Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk (Alliance A031203 CABOSUN Randomised Trial): Progression-Free Survival by Independent Review and Overall Survival UpdateApril 2018

Press Mentions

  • NEUVOGEN Appoints Dr. Mark W. Frohlich, a World-Renowned Immunotherapy Expert to Its Board of Directors and Scientific Advisory Board
    NEUVOGEN Appoints Dr. Mark W. Frohlich, a World-Renowned Immunotherapy Expert to Its Board of Directors and Scientific Advisory BoardAugust 23rd, 2021
  • Trial Update for Apalutamide in Nonmetastatic Castration-Resistant Prostate Cancer
    Trial Update for Apalutamide in Nonmetastatic Castration-Resistant Prostate CancerFebruary 14th, 2019
  • UCSF and MGH: Apalutamide Delays Progression of Nonmetastatic, Castration-Resistant Prostate Cancer
    UCSF and MGH: Apalutamide Delays Progression of Nonmetastatic, Castration-Resistant Prostate CancerFebruary 8th, 2018
  • Join now to see all

Grant Support

  • Prostate Cancer ProgramNational Cancer Institute2007–2011
  • 04557: A Phase I/II Study Of Docetaxel/Prednisone And PTK 787/Zk 222584 In PRNational Center For Research Resources2005
  • Effects Of Bicalutamide Monotherapy On Bone Density In Prostate CancerNational Center For Research Resources2004–2005
  • Evaluation Of Continuous Infusion Gallium Nitrate For Advanced Bladder CarcinomaNational Center For Research Resources1997
  • Study Of Pyrazoloacridine For Treatment Of Hormone Refractory Prostate CancerNational Center For Research Resources1996–1997
  • Evaluation Of Continuous Infusion Gallium Nitrate For Advanced Bladder CancerNational Center For Research Resources1996

Hospital Affiliations